2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147954
    α-Glycosidase-IN-1 2428389-66-4 98%
    α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonic anhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy.
    α-Glycosidase-IN-1
  • HY-147955
    hCAI/II-IN-5 2428389-67-5 98%
    hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy.
    hCAI/II-IN-5
  • HY-147956
    hCA VB-IN-1 98%
    hCA VB-IN-1 (compound 15) is a potent and selective hCA VB (carbonic anhydrase) inhibitor, with a KI of 515.7 nM.
    hCA VB-IN-1
  • HY-147964
    α-Glucosidase-IN-9 735273-33-3 98%
    α-Glucosidase-IN-9 (compound 7) is a potent α-glucosidase inhibitor, with an IC50 of 55.6 μM. α-Glucosidase-IN-9 can be used for type II diabetes research.
    α-Glucosidase-IN-9
  • HY-147965
    α-Glucosidase-IN-10 2586282-68-8 98%
    α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor, with an IC50 of 92.7 μM. α-Glucosidase-IN-10 can be used for type II diabetes research.
    α-Glucosidase-IN-10
  • HY-147987
    FFA1 agonist-1 2417231-16-2 98%
    FFA1 agonist-1 (Compound 17a) is an orally active fatty acid receptor 1 (FFA1) agonist with an EC50 of 0.75 μM. FFA1 agonist-1 can be used for type 2 diabetes mellitus research.
    FFA1 agonist-1
  • HY-14811A
    Beloranib hemioxalate 529511-79-3 98%
    Beloranib (ZGN-440; CKD-732 free base) hemioxalate is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib hemioxalate blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib hemioxalate significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib hemioxalate also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib hemioxalate can be used in research on obesity and hypothalamic obesity.
    Beloranib hemioxalate
  • HY-148210
    AMPK activator 9 1858204-23-5 98%
    AMPK activator 9 (ZM-6) is a potent AMPK (α2β1γ1) activator with an EC50 value of 1.1 µM. AMPK activator 9 has the potential for the research of type 2 diabetes.
    AMPK activator 9
  • HY-148218
    Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanyl-D-alanine 306748-45-8 98%
    Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanyl-D-alanine is a specific peptide substrate of Streptomyces R1 d-alanyl-d-alanine(dd)-peptidases.
    Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanyl-D-alanine
  • HY-148235
    TP-051 858097-86-6 98%
    TP-051, a chemical probe, is a potent FFAR1 agonist with an Ki value of 16 nM for human FFAR1. TP-051 can increase insulin secretion in rat insulinoma cells. TP-051 can be used to research type 2 diabetes.
    TP-051
  • HY-14823G
    Sobetirome (GMP) 211110-63-3
    Sobetirome (GMP) is Sobetirome (HY-14823) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM.
    Sobetirome (GMP)
  • HY-148247
    BI-2081 1458656-71-7 98%
    BI-2081, a chemical probe, is a GPR40 (FFAR1) partial agonist (EC50: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2.
    BI-2081
  • HY-14829F
    L-Afegostat 202979-51-9 98%
    L-Afegostat (5-epi-Isofagomine) is a glycosidase inhibitor. L-Afegostat is an iminosugar that can be used for the synthesis of carbohydrates. L-Afegostat shows enzyme inhibition to β-Glucosidase with an Ki of 30 μM.
    L-Afegostat
  • HY-148322
    Sirtuin modulator 5 694469-31-3 98%
    Sirtuin modulator 5 is a sirtuin modulating agent. Sirtuin modulator 5 can activate SIRT1 with a DC50 value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity.
    Sirtuin modulator 5
  • HY-14832S
    Ataluren-d4 1922064-61-6 98%
    Ataluren-d4 (PTC124-d4) is the deuterium labeled Ataluren (HY-14832). Ataluren (PTC124) is an orally available CFTR-G542X nonsense allele inhibitor.
    Ataluren-d4
  • HY-148475
    (R)-SEMBL 1443449-07-7 98%
    (R)-SEMBL (compound 1B) is a potent NF-κB inhibitor. (R)-SEMBL can be used for the research of cancer, inflammation, autoimmune diseases, diabetes and diabetes complications, infections, cardiovascular disease and defective reperfusion injury.
    (R)-SEMBL
  • HY-148526
    β2AR/M3-receptor agonist-1 1206887-00-4 98%
    β2AR/M3-receptor agonist-1 (example 9) is a potent β2AR and M3 receptor agonist. β2AR/M3-receptor agonist-1 shows M3 receptor affinity with a pIC50 value of 9.3. β2AR/M3-receptor agonist-1 has the potential for the research of respiratory tract disorders.
    β2AR/M3-receptor agonist-1
  • HY-148573
    sEH inhibitor-14 2890221-26-6 98%
    sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC50=0.39 nM).
    sEH inhibitor-14
  • HY-148575
    α-Glucosidase-IN-23 161187-57-1 98.37%
    α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC50 value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes.
    α-Glucosidase-IN-23
  • HY-148600
    HTS13286 727359-12-8 98.98%
    HTS13286 is a novel AQP9 inhibitor. HTS13286 prevents the LPS-induced increase of NO. HTS13286 reduces glucose output. HTS13286 can be used in the research of endotoxin shock.
    HTS13286
Cat. No. Product Name / Synonyms Application Reactivity